Package Leaflet:Information for the patient
Quetiapina Krka 400 mg prolonged-release tablets EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What Quetiapina Krka is and what it is used for
2.What you need to know before you start taking Quetiapina Krka
3.How to take Quetiapina Krka
4.Possible side effects
5.Storage of Quetiapina Krka
6.Contents of the pack and additional information
Quetiapina Krka contains a substance called quetiapine. It belongs to a group of medicines called antipsychotics. Quetiapina Krka may be used to treat several conditions, such as:
When using Quetiapina Krka to treat major depressive episodes in major depressive disorder, it will be taken in addition to another medicine that you are already using to treat this condition.
Your doctor may continue prescribing Quetiapina Krka even if you feel better.
Do not take Quetiapina Krka:
- some HIV medicines
- azole-type medicines (for fungal infections)
- erythromycin or clarithromycin (for infections)
- nefazodone (for depression).
If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Quetiapina Krka if:
Inform your doctor immediately if you experience any of the following after taking quetiapine:
These conditions may be caused by this type of medicine.
Inform your doctor as soon as possible if you have:
Thoughts of suicide and worsening of depression
If you are depressed, you may sometimes think about harming yourself or committing suicide. This may increase when you first start treatment, as all these medicines take time to work, usually around two weeks but sometimes longer. These thoughts may also increase if you stop taking your medication abruptly. You may be more likely to think this way if you are a young adult. Information from clinical trials has shown an increased risk of thoughts of suicide and/or suicidal behavior in young adults under 25 with depression.
If you ever think about harming yourself or committing suicide, contact your doctor or go to the hospital immediately. It may help to tell a close family member or friend that you are depressed, and ask them to read this leaflet. You may ask them to tell you if they think your depression is getting worse, or if they are concerned about changes in your behavior.
Severe cutaneous adverse reaction (SCAR)
Severe cutaneous adverse reactions (SCARs), which may put your life at risk or be fatal, have been reported very rarely with quetiapine treatment. These have often been:
Stop using Quetiapina Krka if you develop these symptoms and contact your doctor or seek medical attention immediately.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
Quetiapine is not used in children and adolescents under 18 years.
Other medicines and Quetiapina Krka
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Do not take quetiapine if you are using any of the following medicines:
Inform your doctor if you are taking any of the following medicines:
Consult your doctor before stopping any of your medicines.
Quetiapina Krka with food, drinks, and alcohol
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medicine.
Do not take this medicine during pregnancy unless you have discussed it with your doctor. Quetiapina Krka should not be taken if you are breastfeeding.
The following symptoms, which may represent withdrawal syndrome, may appear in newborn babies of mothers who have used Quetiapina Krka in the last trimester (last three months of pregnancy): tremor, muscle stiffness, and/or weakness, drowsiness, agitation, respiratory problems, and feeding difficulties. If your newborn develops any of these symptoms, you may need to contact your doctor.
Driving and operating machines
Quetiapina Krka may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may decrease your reaction time. These effects, as well as the underlying illness, may impair your ability to drive vehicles or operate machines. Therefore, do not drive, operate machines, or engage in other activities that require special attention until your doctor assesses your response to this medicine.
Quetiapina Krka contains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have a lactose intolerance, consult them before taking this medicine.
This medicine contains 23.46 mg of sodium (main component of table salt/for cooking) in each 400 mg prolonged-release tablet. This is equivalent to 1.17% of the recommended daily maximum sodium intake for an adult.
Effect on drug detection tests in urine
If you are undergoing a drug detection test in urine, taking quetiapine may produce positive results for methadone or certain antidepressant medicines called tricyclic antidepressants (TCAs) when using some analysis methods, although you may not be taking methadone or TCAs. If this occurs, a more specific test may be performed.
Your doctor will decide your initial dose. The maintenance dose (daily dose) will depend on your illness and your needs, but it will normally be between 150mg and 800mg.
Liver problems
If you have liver problems, your doctor may change your dose.
Older adults
If you are an older adult, your doctor may change your dose.
Use in children and adolescents
Quetiapina Krkashould not be used in children and adolescents under 18 years old.
If you take moreQuetiapina Krkathan you should
If you take moreQuetiapina Krkathan your doctor prescribed, you may feel drowsy, feel dizzy, and experience abnormal heartbeats. Contact your doctor or the nearest hospital immediately. Bring your Quetiapina Krka tablets with you.
You can also call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to takeQuetiapina Krka
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, wait until then. Do not take a double dose to make up for the missed doses.
If you interrupt the treatment withQuetiapina Krka
If you stop taking Quetiapina Krka abruptly, you may be unable to sleep (insomnia), or you may feel nausea, or you may experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest reducing the dose gradually before interrupting treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Side effects of unknown frequency (cannot be estimated from available data)
The class of medicines to which Quetiapina Krka belongs can cause heart rhythm problems that can be serious and, in severe cases, fatal.
Some side effects are only seen when a blood test is done. These include changes in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increases in liver enzymes, decreases in the number of certain types of blood cells, decreases in the number of red blood cells, increases in creatine phosphokinase in the blood (a substance found in muscles), decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood. Prolactin increases may, in rare cases, lead to the following:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents.
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been seen in adults:
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe blister pack and the packagingafter CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
This medication does not require any special storage temperature.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGREpoint of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina Krka
Appearance of the product and contents of the package
The prolonged-release tablets of 400 mg are white or almost white, in the form of a capsule, biconvex, coated with a film and engraved with “400” on one of the faces. Dimensions of the tablet: 18.7 – 19.5 mm in diameter and 5.5 – 7.1 mm in thickness.
Quetiapina Krka 400 mg prolonged-release tablets are available in packages containing 10, 30, 50, 60, 90 and 100 prolonged-release tablets in OPA/Al/PVC-Al blisters.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann Str. 5, 27472 Cuxhaven, Germany
Further information about this medicinal product can be obtained by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, 28108, Alcobendas, Madrid, Spain
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Member state name | Medicinal product name |
Austria | Quetiapin HCS |
Denmark, Finland, Iceland, Sweden | Quetiapin Krka |
Belgium | Quetiapine Krka |
Bulgaria | ????????? SR |
Czech Republic | KventiaxProlong |
Estonia, Poland, Slovak Republic, Slovenia | Kventiax SR |
France | Quétiapine Krka LP |
Greece | Arezil XR |
Ireland | Quentiax SR |
Germany | Quetiapin TAD |
Italy | Quentiax |
Latvia, Lithuania | Kventiax |
Portugal, Spain | Quetiapina Krka |
Romania | Kventiax EP |
Last review date of this leaflet: December 2021
Further detailed information about this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.